JP2004505992A - ワクチンに使用するためのｈｂｖ抗原の精製 - Google Patents

ワクチンに使用するためのｈｂｖ抗原の精製 Download PDF

Info

Publication number
JP2004505992A
JP2004505992A JP2002518258A JP2002518258A JP2004505992A JP 2004505992 A JP2004505992 A JP 2004505992A JP 2002518258 A JP2002518258 A JP 2002518258A JP 2002518258 A JP2002518258 A JP 2002518258A JP 2004505992 A JP2004505992 A JP 2004505992A
Authority
JP
Japan
Prior art keywords
antigen
hepatitis
thiomersal
vaccine
cysteine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002518258A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004505992A5 (enExample
Inventor
デ　ヘイデル，コーエン
シュー，ピーター
セラントニ，ミッシェル
ファン　オプステル，オマー
Original Assignee
グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0019728.5A external-priority patent/GB0019728D0/en
Priority claimed from GB0101334A external-priority patent/GB0101334D0/en
Application filed by グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム filed Critical グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム
Publication of JP2004505992A publication Critical patent/JP2004505992A/ja
Publication of JP2004505992A5 publication Critical patent/JP2004505992A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2002518258A 2000-08-10 2001-08-07 ワクチンに使用するためのｈｂｖ抗原の精製 Pending JP2004505992A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0019728.5A GB0019728D0 (en) 2000-08-10 2000-08-10 Novel treatment
GB0101334A GB0101334D0 (en) 2001-01-18 2001-01-18 Novel compounds
PCT/EP2001/009100 WO2002012287A1 (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012180462A Division JP5559847B2 (ja) 2000-08-10 2012-08-16 ワクチンに使用するためのｈｂｖ抗原の精製

Publications (2)

Publication Number Publication Date
JP2004505992A true JP2004505992A (ja) 2004-02-26
JP2004505992A5 JP2004505992A5 (enExample) 2005-03-03

Family

ID=26244821

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002518258A Pending JP2004505992A (ja) 2000-08-10 2001-08-07 ワクチンに使用するためのｈｂｖ抗原の精製
JP2012180462A Expired - Lifetime JP5559847B2 (ja) 2000-08-10 2012-08-16 ワクチンに使用するためのｈｂｖ抗原の精製

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012180462A Expired - Lifetime JP5559847B2 (ja) 2000-08-10 2012-08-16 ワクチンに使用するためのｈｂｖ抗原の精製

Country Status (35)

Country Link
US (3) US20030235590A1 (enExample)
EP (2) EP1307473B1 (enExample)
JP (2) JP2004505992A (enExample)
KR (1) KR100804922B1 (enExample)
CN (1) CN1468256B (enExample)
AP (1) AP2003002734A0 (enExample)
AR (1) AR030325A1 (enExample)
AT (2) ATE313558T1 (enExample)
AU (2) AU2001282073B2 (enExample)
BG (1) BG66038B1 (enExample)
BR (1) BRPI0113155C1 (enExample)
CA (2) CA2740282A1 (enExample)
CY (2) CY1106310T1 (enExample)
CZ (1) CZ303217B6 (enExample)
DE (2) DE60116107T2 (enExample)
DK (2) DK1666487T3 (enExample)
DZ (1) DZ3470A1 (enExample)
EA (1) EA006433B1 (enExample)
EG (1) EG25829A (enExample)
ES (2) ES2314555T3 (enExample)
HU (1) HU228932B1 (enExample)
IL (2) IL154301A0 (enExample)
MX (1) MXPA03001235A (enExample)
MY (1) MY128999A (enExample)
NO (1) NO20030635L (enExample)
NZ (1) NZ524012A (enExample)
OA (1) OA12361A (enExample)
PE (1) PE20020287A1 (enExample)
PL (1) PL204736B1 (enExample)
PT (1) PT1666487E (enExample)
SI (2) SI1666487T1 (enExample)
SK (2) SK288079B6 (enExample)
UA (1) UA79735C2 (enExample)
UY (1) UY26882A1 (enExample)
WO (1) WO2002012287A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009503051A (ja) * 2005-08-02 2009-01-29 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 油含有アジュバントと界面活性剤含有アジュバントとの間の干渉の減少
JP2009514942A (ja) * 2005-11-08 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Ｂ型肝炎ウイルス表面抗原および界面活性剤の両方を含むワクチンの製造
JP2010502678A (ja) 2006-09-07 2010-01-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
JP2012528106A (ja) * 2009-05-27 2012-11-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｃａｓｂ７４３９構築物

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
GB0202901D0 (en) * 2002-02-07 2002-03-27 Glaxosmithkline Biolog Sa Novel vaccine
SG163572A1 (en) * 2005-07-11 2010-08-30 Globeimmune Inc Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
GB0612142D0 (en) 2006-06-20 2006-08-02 Secr Defence Spreading modulation spectrum control
JP2010525035A (ja) 2007-05-02 2010-07-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
WO2009057699A1 (ja) * 2007-10-30 2009-05-07 Kyocera Corporation 弾性波装置
US8250102B2 (en) * 2008-03-14 2012-08-21 Microsoft Corporation Remote storage and management of binary object data
KR100959145B1 (ko) 2008-03-21 2010-05-25 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사 입자의 생산 및 정제 방법
WO2009143524A2 (en) * 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Nanoemulsion vaccines
PT2705365T (pt) * 2011-01-14 2016-09-19 Hal Allergy Holding B V Imunoensaio para determinação direta do teor de antigénio de produtos compreendendo partículas de antigénio acoplado a adjuvante
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
CN106222129A (zh) * 2016-07-29 2016-12-14 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
CN111032078A (zh) 2017-07-18 2020-04-17 血清研究所印度私人有限公司 具有改善的稳定性、增强的免疫原性和降低的反应原性的免疫原性组合物及其制备方法
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
CA3132601A1 (en) 2019-03-05 2020-09-10 Glaxosmithkline Biologicals Sa Hepatitis b immunisation regimen and compositions
CN112972671B (zh) * 2019-12-13 2024-04-19 远大赛威信生命科学(南京)有限公司 药物组合物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61249398A (ja) * 1985-04-03 1986-11-06 スミスクライン・バイオロジカルス・ソシエテ・アノニム タンパク質産生培地からのｂ型肝炎表面抗原の抽出精製方法
WO1996012802A1 (en) * 1989-10-31 1996-05-02 Ophidian Pharmaceuticals, Inc. Vaccine and antitoxin for treatment and prevention of c. difficile disease
WO2000037104A1 (en) * 1998-12-23 2000-06-29 Merck & Co., Inc. Improved recombinant hepatitis b surface antigen

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1030777A (en) * 1963-12-06 1966-05-25 Ciba Ltd Method of preparing a vaccine against trypanosoma cruzi infections
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4720385A (en) * 1983-03-29 1988-01-19 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
JPS6013718A (ja) 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン
EP0135435A3 (en) 1983-08-22 1987-03-25 Merck & Co. Inc. Immunogenic hbsag derived from transformed yeast
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
AP56A (en) 1987-01-30 1989-09-26 Smithkline Biologicals S A Hepatitis B virus surface antigens and hybrid antigehs containing them.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP1088830A3 (en) 1987-06-22 2004-04-07 Medeva Holdings B.V. Hepatitis b surface antigen particles
DE3789866T2 (de) 1987-07-17 1994-09-22 Rhein Biotech Gesellschaft Fuer Neue Biotechnologische Prozesse Und Produkte Mbh, 40595 Duesseldorf DNA-Moleküle, die für FMDH-Kontrollabschnitte und Strukturgene für ein Protein mit FMDH-Aktivität kodieren, sowie deren Anwendung.
EP0314240A3 (en) * 1987-10-26 1990-03-28 Merck & Co. Inc. Process for purifying recombinant hepatitis antigens
JPH085804B2 (ja) 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5242812A (en) * 1989-02-07 1993-09-07 Bio-Technology General Corp. Method for production and purification of hepatitis B vaccine
US5274081A (en) * 1989-09-20 1993-12-28 Immuno A.G. Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
EP0563091A1 (en) 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines based on hepatitis b surface antigen
JP3026029B2 (ja) 1991-04-26 2000-03-27 財団法人阪大微生物病研究会 組換え水痘ウイルスとその作製法
CA2096650A1 (en) 1991-09-18 1993-03-21 Keith E. Langley Hepatitis b vaccine formulation incorporating a bile acid salt
US6620414B2 (en) * 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
KR960023066A (ko) * 1994-12-10 1996-07-18 성재갑 전에스 (s) 2 펩티드 함유 비 (b) 형 간염 표면항원의 정제 방법
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
NZ506602A (en) * 1998-03-09 2003-02-28 Smithkline Beecham Biolog S Combined vaccine compositions against hepatitis B virus and herpes simplex virus and possibly also epstein bar virus, hepatitis A & C viruses, human papilloma virus, varicella zoster virus, human cytomegalovirus, and toxoplasma gondii
PT1104306E (pt) 1998-08-10 2006-05-31 Antigenics Inc Composicoes de cpg e adjuvantes de saponina e seus metodos
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61249398A (ja) * 1985-04-03 1986-11-06 スミスクライン・バイオロジカルス・ソシエテ・アノニム タンパク質産生培地からのｂ型肝炎表面抗原の抽出精製方法
WO1996012802A1 (en) * 1989-10-31 1996-05-02 Ophidian Pharmaceuticals, Inc. Vaccine and antitoxin for treatment and prevention of c. difficile disease
WO2000037104A1 (en) * 1998-12-23 2000-06-29 Merck & Co., Inc. Improved recombinant hepatitis b surface antigen

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009503051A (ja) * 2005-08-02 2009-01-29 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 油含有アジュバントと界面活性剤含有アジュバントとの間の干渉の減少
JP2009514942A (ja) * 2005-11-08 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Ｂ型肝炎ウイルス表面抗原および界面活性剤の両方を含むワクチンの製造
JP2013056940A (ja) * 2005-11-08 2013-03-28 Novartis Vaccines & Diagnostics Srl Ｂ型肝炎ウイルス表面抗原および界面活性剤の両方を含むワクチンの製造
JP2010502678A (ja) 2006-09-07 2010-01-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
JP2013256505A (ja) * 2006-09-07 2013-12-26 Glaxosmithkline Biologicals Sa ワクチン
JP2016020361A (ja) * 2006-09-07 2016-02-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
JP2012528106A (ja) * 2009-05-27 2012-11-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｃａｓｂ７４３９構築物

Also Published As

Publication number Publication date
CY1108789T1 (el) 2014-04-09
SI1666487T1 (sl) 2009-02-28
HUP0302951A2 (hu) 2003-12-29
AU8207301A (en) 2002-02-18
UY26882A1 (es) 2002-03-22
NZ524012A (en) 2004-02-27
AP2003002734A0 (en) 2003-03-31
US20030235590A1 (en) 2003-12-25
DE60116107D1 (de) 2006-01-26
ES2254464T3 (es) 2006-06-16
ES2314555T3 (es) 2009-03-16
AR030325A1 (es) 2003-08-20
BRPI0113155C1 (pt) 2021-05-25
SI1307473T1 (sl) 2006-04-30
ATE313558T1 (de) 2006-01-15
CA2427475C (en) 2011-07-05
UA79735C2 (uk) 2007-07-25
ATE412665T1 (de) 2008-11-15
PT1666487E (pt) 2008-12-26
NO20030635L (no) 2003-04-01
CA2427475A1 (en) 2002-02-11
EA006433B1 (ru) 2005-12-29
WO2002012287A1 (en) 2002-02-14
CZ2003385A3 (cs) 2003-06-18
DK1307473T3 (da) 2006-05-01
AU2001282073B2 (en) 2005-01-20
SK1692003A3 (en) 2003-08-05
EP1666487B1 (en) 2008-10-29
CA2740282A1 (en) 2002-02-11
JP5559847B2 (ja) 2014-07-23
PL362322A1 (en) 2004-10-18
BRPI0113155B1 (pt) 2018-11-21
BG66038B1 (bg) 2010-11-30
MY128999A (en) 2007-03-30
HK1056884A1 (en) 2004-03-05
EA200300129A1 (ru) 2003-10-30
NO20030635D0 (no) 2003-02-07
EP1307473A1 (en) 2003-05-07
DZ3470A1 (fr) 2002-02-14
OA12361A (en) 2004-04-13
IL154301A0 (en) 2003-09-17
US20060159705A1 (en) 2006-07-20
DE60136400D1 (de) 2008-12-11
MXPA03001235A (es) 2004-07-16
HU228932B1 (en) 2013-06-28
US8624004B2 (en) 2014-01-07
EG25829A (en) 2012-09-02
SK288079B6 (sk) 2013-06-03
IL154301A (en) 2009-11-18
BG107545A (bg) 2004-01-30
DK1666487T3 (da) 2009-01-12
US20090123496A1 (en) 2009-05-14
CY1106310T1 (el) 2011-10-12
JP2012255015A (ja) 2012-12-27
CN1468256A (zh) 2004-01-14
BR0113155A (pt) 2003-07-08
DE60116107T2 (de) 2006-08-03
SK288069B6 (sk) 2013-05-03
CN1468256B (zh) 2010-10-27
KR100804922B1 (ko) 2008-02-20
HUP0302951A3 (en) 2004-10-28
PE20020287A1 (es) 2002-06-20
EP1307473B1 (en) 2005-12-21
EP1666487A1 (en) 2006-06-07
BRPI0113155B8 (pt) 2019-08-13
CZ303217B6 (cs) 2012-05-30
PL204736B1 (pl) 2010-02-26
KR20030029127A (ko) 2003-04-11

Similar Documents

Publication Publication Date Title
JP5559847B2 (ja) ワクチンに使用するためのｈｂｖ抗原の精製
AU2001282073A1 (en) Purification of HBV antigens for use in vaccines
KR100365373B1 (ko) B형간염백신
WO2003066094A2 (en) Hepatitis b vaccines
EP0005864B1 (en) Antigenic composition useful as a vaccine or vaccine intermediate, and process for preparing same
JP4974441B2 (ja) 抗原性凝集物を得る方法と製剤におけるその使用
NO20130773L (no) Metode for fremstilling av en vaksine
TWI311563B (en) Method for production a stable,immunogenic hepatitis b vaccine without trace of thiomersal
HK1056884B (en) Purification of hbv antigens for use in vaccines

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110425

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110808

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120816